High-Voltage Long-Duration Pulsed Radiofrequency Combined with Liposomal Bupivacaine Subcutaneous Block in the Treatment of Herpes Zoster-Associated Neuralgia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500100961

Enrollment

Unknown

Registered

2025-04-17

Start date

2025-01-09

Completion date

Unknown

Last updated

2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes Zoster-Associated Neuralgia

Interventions

HL-PRF+LB group:High-Voltage Long-Duration Pulsed Radiofrequency Combined with Liposomal Bupivacaine Subcutaneous Block

HL-PRF group:High-Voltage Long-Duration Pulsed Radiofrequency

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with zoster-associated neuralgia (ZAN) who meet ALL of the following conditions: 1.Voluntarily provided written informed consent; 2.Inadequate response to pharmacological or other non-surgical therapies OR intolerable drug-related adverse effects; 3.Herpes zoster (HZ) lesions involving cranial/cervicocephalic, cervical, thoracic, or lumbar dermatomes; 4.Moderate-to-severe pain intensity, defined as a Numerical Rating Scale (NRS) score >=4 at baseline; 5.Aged between 40 and 85 years; 6.Body weight: Male >=50 kg; female >=45 kg.

Exclusion criteria

Exclusion criteria: 1. Severe cardiovascular diseases or life-threatening arrhythmias (e.g., heart failure, third-degree atrioventricular block without pacemaker implantation); 2. Contraindications to minimally invasive interventions (e.g., coagulation disorders, active infections); 3. Allergy to local anesthetics or lipid emulsions; 4. Severe dysfunction of vital organs (cardiac, pulmonary, hepatic, or renal) rendering the patient unfit for the procedure; 5. Severe endocrine disorders or long-term use of corticosteroids/immunosuppressive agents; 6. Cognitive impairment or inability to cooperate with treatment protocols; 7. Prior history of neuromodulation therapies (e.g., spinal cord stimulation or pulsed radiofrequency (PRF) treatment).

Design outcomes

Primary

Measure	Time frame
NRS;	—

Secondary

Measure	Time frame
Zoster Brief Pain Inventory, ZBPI;Pittsburgh Sleep Quality Index Scale;Use of analgesics (tramadol, gabapentin, or pregabalin);Adverse event rate;Expression levels of complete blood count (CBC), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) in patients during the preoperative and 1-day postoperative periods.;	—

Countries

China

Contacts

Public ContactShirong Tan

Affiliated Hospital of Zunyi Medical University

15085046515@163.com+86 150 8504 6515

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026